Gt Biopharma Stock Today
| GTBP Stock | USD 2.06 0.05 2.37% |
Performance0 of 100
| Odds Of DistressOver 85
|
GT Biopharma is selling at 2.06 as of the 31st of January 2025; that is 2.37 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.02. GT Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 3rd of September 2024 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of September 2017 | Category Healthcare | Classification Health Care |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager fusion protein immune cell engager technology platform. GT Biopharma, Inc. The company has 2.23 M outstanding shares of which 186.91 K shares are currently shorted by private and institutional investors with about 0.71 trading days to cover. More on GT Biopharma
Moving against GTBP Stock
| 0.6 | MLAB | Mesa Laboratories Earnings Call This Week | PairCorr |
| 0.34 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
GTBP Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Name | GT Biopharma Inc | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGT Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand GT Biopharma's financial leverage. It provides some insight into what part of GT Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
GT Biopharma (GTBP) is traded on NASDAQ Exchange in USA. It is located in 8000 Marina Boulevard, Brisbane, CA, United States, 94005 and employs 2 people. GT Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.23 M. GT Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.23 M outstanding shares of which 186.91 K shares are currently shorted by private and institutional investors with about 0.71 trading days to cover.
GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Check GT Biopharma Probability Of Bankruptcy
Ownership AllocationOver half of GT Biopharma's outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions.
Check GTBP Ownership Details
GTBP Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-09-30 | 27.0 | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 12.0 | |
| Blue Bell Private Wealth Management, Llc | 2024-09-30 | 10.0 | |
| Bnp Paribas Arbitrage, Sa | 2024-09-30 | 6.0 | |
| Royal Bank Of Canada | 2024-09-30 | 5.0 | |
| Jpmorgan Chase & Co | 2024-09-30 | 1.0 | |
| Front Row Advisors Llc | 2024-09-30 | 0.0 | |
| Fmr Inc | 2024-06-30 | 0.0 | |
| Dekabank Deutsche Girozentrale | 2024-09-30 | 1.2 M | |
| Bank Of Montreal | 2024-09-30 | 29.9 K | |
| Bmo Capital Markets Corp. | 2024-09-30 | 29.9 K |
GT Biopharma Historical Income Statement
GTBP Stock Against Markets
GT Biopharma Corporate Management
| Michael Breen | Interim Chairman | Profile | |
| Manu Ohri | Chief Officer | Profile | |
| Jeffrey MD | Consulting Advisor | Profile | |
| Gregory MD | Chief RD | Profile | |
| MPH MBA | VP Management | Profile | |
| PharmD MBA | Chief Officer | Profile | |
| Alan CPA | Chief Officer | Profile |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.